The Strategic Role of Epigenetic and Microbiome Interactions in Managing Inflammation-Driven Risks in Diet-Related Obesity

Abstract

There is mounting evidence that microbiomes, also known as epigenomes, have a role in metabolic health and the inflammation linked to diet-induced obesity (DIO). This work examines the interaction between DIO, the epigenomic landscape, and the makeup of the microorganisms in the digestive tract within the setting of endocannabinoid-mediated inflammatory control in a mouse model. The negative effects of a high-fat diet (HFD) might be studied by first making C57BL/6J mice overweight and then monitoring their weight. Determining if there were alterations in metabolic parameters or inflammatory indicators was the primary objective. Researchers discovered changes in DNA methylation patterns linked to obesity by integrating genomic sequencing with epigenetic profiling. At the same time, scientists analysed the gut microbiota using 16S rRNA sequencing and found that the HFD was associated with major changes in the variety and composition of microbes. Researchers assessed the impact on inflammatory responses and metabolic repercussions after pharmaceutically modifying endocannabinoid signalling in order to identify the pathways. Inflammation in DIO is influenced by both the microbiota and the epigenome, as previously shown. Then, this influences the signalling of endogenous cannabinoids. While further study is required to clarify the precise processes at play and their relevance to obesity prevention and treatment, the present study does draw attention to the intricate relationship between the microbiome, nutrition, and epigenetic pathways as they pertain to metabolic health, as well as the possibility of using these pathways as therapeutic targets for the inflammation that accompanies obesity.